References
- Nikolaou V, Papadavid E, Economidi A, et al. Mycosis fungoides in the era of antitumour necrosis factor-alpha treatments. Br J Dermatol. 2015;173:590–593.
- Lafaille P, Bouffard D, Provost N. Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. Arch Dermatol. 2009;145:94–95.
- Suga H, Sugaya M, Toyama T, et al. A case of mycosis fungoides with large cell transformation associated with infliximab treatment. Acta Derm Venereol. 2014;94:233–234.
- Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126:2194–2201.
- Nikolaou V, Marinos L, Moustou E, et al. Psoriasis in patients with mycosis fungoides: a clinicopathological study of 25 patients. J Eur Acad Dermatol Venereol. 2017;31:1848–1852.
- Freling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110:1186–1196.
- Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidem Drug Safe. 2011;20:119–130.
- Mocci G, Marzo M, Papa A, et al. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013;7:769–779.
- Deepak P, Sifuentes H, Sherid M, et al. T cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99–105.
- Dalle S, Balme B, Berger F, et al. Mycosis fungoides-associated follicular mucinosis under adalimumab. Br J Dermatol. 2005;153:207–208.
- Lourari S, Prey S, Livideanu C, et al. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases. J Eur Acad Dermatol. 2009;23:967–968.
- Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med. 1999;341:1817–1828.
- Imafuku S, Ito K, Nakayama J. Cutaneous pseudolymphoma induced by adalimumab and reproduced by infliximab in a patient with arthropathic psoriasis. Br J Dermatol. 2012;166:675–678.
- Nguyen K, Vleugels RA, Velez NF, et al. Psoriasiform Reactions to anti-tumor necrosis factor alpha therapy. J Clin Rheumatol. 2013;19:377–381.
- Hawryluk EB, Linskey KR, Duncan LM, et al. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012;39:481–492.